Vertex Pharmaceuticals and CRISPR Therapeutics made history last month by gaining approval for the first CRISPR-based drug, exagamglogene autotemcel (Casgevy). However, given that 88% of CRISPR drugs are in the early stages of development, it is unlikely to see another CRISPR approval any time soon, says GlobalData, a leading data and analytics company. In November […]
